Japan & South Korea's Cannabis Reforms: Asia's Cautious Path
Photo via Pexels.
Two headlines out of Tokyo and Seoul in the same eighteen-month window look like they're describing opposite countries. Japan just made it easier, for the first time in its history, for a licensed physician to prescribe a cannabis-derived medicine. Japan also just sent a person to trial for using cannabis, something the old law technically couldn't touch. South Korea, which has quietly imported named cannabis pharmaceuticals since 2018, is now debating a bill to build its own cultivation and extraction infrastructure so it doesn't have to import them at all -- while consumer CBD stays flatly illegal, seized at the border without exception. Read as isolated news items, these look contradictory: loosen with one hand, tighten with the other.
Read together, they're not contradictory at all. They're the same policy design, executed on two different timelines by two governments with a shared regulatory instinct. Japan's revised Cannabis Control Act took effect on December 12, 2024, the most significant rewrite of the country's cannabis law in decades, and within three months Tokyo police had made the country's first arrests for cannabis use itself -- a category of offense that simply didn't exist under the old statute. South Korea, first in East Asia to legalize medical cannabis imports back in November 2018, is now weighing a 2026 amendment that would let it manufacture cannabis-based pharmaceuticals domestically rather than remain permanently dependent on foreign supply. Neither country is opening a dispensary door. Both are opening a pharmacy counter, guarded more tightly than before. That's the throughline worth tracking, because it's a model other Asian governments can borrow wholesale -- and several are watching closely enough that they probably will.
Japan's 2024 Law: Medicine In, Users Punished Harder
Japan's revised Cannabis Control Act is the country's first substantial cannabis policy rewrite since the postwar occupation-era statute that created the current framework. It took effect December 12, 2024, and it does two things at once that are easy to conflate but need to be kept separate. On the medical side, it folds cannabis-derived pharmaceutical products into the same regulatory lane that already governs opioid analgesics -- meaning that, for the first time, a licensed physician in Japan has a legal pathway to prescribe a cannabis-based medicine, provided it clears the same approval process morphine or oxycodone formulations go through. On the industrial side, it lifts a restriction that had stood since the original postwar law: hemp cultivation and processing were previously confined to mature stalks and seeds only, on the theory that those parts carry negligible THC. The new law widens what's permissible but pairs that expansion with an explicit THC concentration threshold, so the loosening is narrow and enforcement-testable rather than a general green light for hemp products.
The part that got less attention outside Japan, but matters more for anyone actually living there, is what the law closed rather than opened. Under the old statute, possessing or selling cannabis was illegal, but using it wasn't specifically criminalized as its own offense -- a genuine, long-standing gap in Japanese drug law. The revised act closes that gap by reclassifying cannabis and THC as narcotics under the Narcotics and Psychotropics Control Law, which means simple use is now its own prosecutable act, carrying a sentence of up to seven years. This isn't a symbolic tightening. Tokyo police made what appear to be the law's first use-based arrests in March 2025, just three months after the statute took effect, using urine tests that detect cannabis metabolites rather than requiring police to catch someone with product in hand. That's a meaningfully lower evidentiary bar than the old possession-only regime required, and it signals that enforcement capacity is already built and active, not theoretical.
The Medical Track: Epidiolex, Orphan Drugs, and a New License Class
Photo via Unsplash.
The medical opening in Japan's new law isn't abstract -- it has a specific product attached to it. In April 2024, several months before the broader Cannabis Control Act amendment took effect, Japan's health ministry designated Epidiolex, the purified CBD formulation already approved in the US and Europe for severe pediatric epilepsy syndromes, as an orphan drug. Orphan drug status in Japan carries real regulatory weight: it fast-tracks review, extends data exclusivity, and signals that regulators intend to actually move a product through approval rather than let it sit in a queue. With the law now in effect, cannabis-derived pharmaceuticals can proceed through Japan's standard New Drug Application process and, once approved, be prescribed by licensed physicians -- a genuine first in Japanese medical practice, even if the initial patient population is narrow.
Domestic cultivation for medicinal purposes doesn't run through anything resembling an open license system. The law creates a new Type II cultivation license issued directly by the national health ministry, which centralizes control over who can grow cannabis for pharmaceutical purposes rather than distributing that authority to prefectures or opening it to general agricultural licensing. That's a deliberate structural choice: it keeps the number of legal cultivators small and directly accountable to the national health ministry, which makes the medical lane easier to police and harder to expand informally.
A peer-reviewed analysis published in Cannabis and Cannabinoid Research in June 2026 frames the amendment in exactly these terms -- as a calculated balance between capturing medical and industrial opportunity while preserving strict drug control, with the authors noting that the practical, on-the-ground effects of the law are still emerging and worth continued study rather than assumed. That's a useful caution for outside observers: the legal architecture is now in place, but how many patients actually get prescriptions, and how fast, remains an open empirical question. What isn't ambiguous is the shape of the opening. There's no path here toward a dispensary network or a consumer wellness market. This is a pharmaceutical channel, full stop, built to run through hospitals and pharmacies the same way any other narcotic-class medicine does in Japan.
South Korea's Import-Only Era Is Ending, Slowly
Photo by yong gil via Pexels.
South Korea holds a distinction worth stating plainly: it was the first country in East Asia to legalize medical cannabis imports, doing so in November 2018 through an amendment to its narcotics laws. But legalizing imports and building an actual medical market are different things, and for most of the seven years since, Korea has run the narrowest possible version of the former. Access has gone through the Korea Orphan Drug Center (also referred to as the Essential Drug Center), on a case-by-case basis, limited to a short, named list of products: Epidiolex, Marinol, Cesamet, and Sativex. There's no broad prescribing framework here -- a patient's physician has to make an individual case for one of these specific, already-approved-elsewhere formulations, and the government facilitates the import on a per-case basis rather than maintaining an open pharmaceutical supply chain.
The real news out of Korea isn't about imports at all -- it's about the push to stop needing them. A 2026 legislative development shifts the conversation from access to production. Opposition lawmaker Kim Hyeong-dong of the People Power Party introduced an amendment to the Narcotics Control Act that would classify therapeutic cannabis substances, including CBD specifically, as psychotropic drugs under Korean law and, critically, establish a legal basis for domestic manufacturing and marketing approval of cannabis-based pharmaceuticals. That's a structurally different ambition than the 2018 import law -- it's Korea deciding it wants to be a producer, not just a purchaser, of these medicines.
The bill's most telling detail is institutional: it proposes creating a Medical Narcotics Raw Material Management Center, which would let the government oversee cultivation, extraction, and finished pharmaceutical production end-to-end, under one roof. That's the South Korean version of Japan's Type II license -- a chokepoint designed into the system from the start, not an oversight to be added later. There's already a small research foothold in place ahead of the bill: in late 2025, Korea's Ministry of Food and Drug Safety approved a pilot allowing limited clinical trials of CBD for epilepsy, the country's first domestic cannabinoid research program. Meanwhile, nothing about consumer or wellness CBD has moved an inch -- it's fully banned, legally treated as a narcotic, and personal imports are seized at customs with no case-by-case exceptions of the kind medical patients get.
Why the Market Numbers Stay Small on Purpose
South Korea's cannabis market is projected to grow steadily from $460.8M in 2024 to $527.8M by 2029, reflecting a modest, consistent annual increase.
Statista's projections put South Korea's cannabis market at $460.8 million in 2024, growing to $527.8 million by 2029 -- a compound annual growth rate of roughly 2.75%. Those are modest numbers for a developed economy, and the modesty isn't an accident of market immaturity. It's what a market looks like when its entire addressable population is pharmaceutical patients accessing named products through a government-run import center, rather than consumers buying from retail shelves. A 2.75% CAGR is roughly what you'd expect from a slow-growing category of prescription medicine in any developed country -- not a frontier market, a mature niche one.
The contrast with markets that opened more broadly is instructive. Germany's April 2024 partial legalization, which allowed home cultivation and non-commercial cannabis clubs, triggered a genuine step-change in consumption and cultivation activity almost immediately, because it converted a large latent consumer base into a legal one overnight. Thailand's 2022-2024 experience shows the same step-change dynamic running in reverse -- a rapid, near-uncontrolled retail boom followed by an equally abrupt policy walk-back as the government moved to restrict recreational sales. Both are volatile, discontinuous curves, driven by consumer demand hitting or leaving a legal channel all at once. Korea's projected curve is the opposite: smooth, linear, low-slope, because pharmaceutical patient populations grow gradually as new indications and products get approved, not in the sudden jumps that come from opening general retail access.
That gives us two readings, and both deserve to be stated rather than picked between blindly. The conservative read is that without a legislative trigger -- broadened physician prescribing authority, or some future move toward OTC CBD that nothing in current Korean politics suggests is coming -- this market stays a rounding error next to Japan's, Australia's, or Thailand's, even as the absolute dollar figure keeps ticking upward. The more speculative read, and one genuinely worth watching rather than dismissing, is that if the domestic production bill and its Raw Material Management Center actually pass, Korea's opportunity shifts from serving its own small patient population to becoming a regional API and raw-material supplier for other tightly regulated Asian pharmaceutical markets that don't want to build cultivation infrastructure themselves. That would make the domestic market size figure almost beside the point -- the business would be exports of pharmaceutical inputs, not domestic patient sales.
The Precedent This Actually Follows: Not the US, Not Europe
Photo by Pavel Danilyuk via Pexels.
It's tempting, especially for anyone who's spent years watching US cannabis policy, to read Japan and Korea's moves as an early stage of the same sequence -- medical access first, decriminalization later, some version of state-by-state or country-by-country cascade eventually arriving at broad legal markets. That's the wrong precedent. Nothing in the last two years of policy activity in either country points toward recreational reform, and the enforcement side of Japan's new law -- criminalizing use itself, with arrests following within three months -- runs directly opposite to what preceded loosening in every US state that legalized. It's also not the German or Thai model, where a government opened broad access first and is now managing the consequences. Japan and Korea are doing neither.
The closer parallel is domestic, not foreign: how each country has historically handled other controlled pharmaceuticals. Japan's own new law makes this explicit by borrowing its regulatory template directly from how opioid analgesics are governed -- same approval pathway, same prescribing structure, same narcotics classification logic applied to a new substance class. That's not a metaphor; it's the literal legal architecture regulators chose. Reasoning forward from Japan's own drug policy history, incremental medical carve-outs preceding any consumer liberalization by a decade or more isn't a break from precedent -- it's the established domestic pattern, going back to how other restricted substances entered Japanese medicine gradually, under tight institutional control, well before any public conversation about broader access even started.
Regional context sharpens what's actually distinctive here. Singapore and mainland China represent the alternative path available to any Asian government: near-total prohibition, no medical carve-out at all, harsh enforcement with no pharmaceutical exception. Against that backdrop, Japan and Korea's willingness to build any legal medical lane, however narrow, is itself the notable regional development -- not a step toward Western-style access, but a third option other governments in the region didn't previously have modeled for them.
The honest counter-case deserves equal weight: harsher enforcement could simply be the durable, permanent state of affairs, with medical access remaining a narrow pharmaceutical niche indefinitely rather than a stepping stone toward anything broader. Japan gives no indication -- none in the text of the law, none in ministry statements, none in how enforcement has actually played out -- that recreational reform sits on any visible horizon. Anyone betting on this being an on-ramp is betting on precedent that Japan itself isn't following.
What This Means for Business Watching the Region
Photo by Gustavo Fring via Pexels.
For companies actually trying to do business in this region over the next few years, the opportunity is real but much narrower than the headlines about Asia's cannabis market suggest. It concentrates almost entirely around firms holding orphan-drug pharmaceutical assets -- Epidiolex-type formulations with existing regulatory approval elsewhere -- rather than raw-material suppliers or consumer brands. Japan's orphan-drug designation for Epidiolex in April 2024 is the template: a company with an already-approved formulation and clinical data from other markets has a plausible route through New Drug Application review. A company with hemp biomass, extraction capacity, or a wellness product line has essentially nothing to sell into either market right now.
Both countries are also building procurement chokepoints rather than open markets, and that's worth internalizing before anyone models a total-addressable-market number. Korea's proposed Medical Narcotics Raw Material Management Center, if the bill passes, would centralize cultivation, extraction, and production procurement under direct government oversight -- meaning the realistic business opportunity is a small number of licensed, government-vetted suppliers, not competitive open bidding. Japan's Type II cultivation license does the same job through a different mechanism, concentrating legal domestic cultivation among a handful of vetted operators rather than seeding a broader ag-tech or cultivation sector the way, say, Canada's licensed-producer system eventually did. Anyone picturing dozens of competing growers should recalibrate: this looks more like a government contractor relationship than a commodity market.
The most useful leading indicator to watch isn't a legislative headline at all -- it's the clinical trial pipeline. Korea's late-2025 approval of a pilot CBD-epilepsy trial is the kind of unglamorous milestone that actually predicts what gets approved next, because trial results typically precede any prescribing expansion by several years in both countries' regulatory systems. Firms and investors tracking this space should treat trial registrations and regulatory approval pilots as the real signal, well ahead of any prescribing rule change making news.
What should be stated without qualification: consumer and wellness CBD brands have no viable legal entry point into either market today, and nothing in either country's 2024-2026 reform activity suggests that changes in the foreseeable future. Personal imports get seized at the Korean border with no exceptions carved out for CBD specifically. Japan's THC threshold structure exists precisely to prevent a general hemp-wellness market from forming under cover of the industrial hemp loosening. Any market-entry strategy premised on Japan or Korea eventually looking like a European CBD retail market is building on an assumption these governments have gone out of their way, twice now, to reject.
What Japan and Korea are demonstrating, in real time and in statute, is that medical cannabis access and stricter criminal enforcement aren't opposing trends fighting for the same policy space -- they can be one coherent package, designed and passed together rather than arrived at through compromise. That's a genuinely useful template, and it's one other Asian governments now have sitting in front of them as a working example rather than a hypothetical. Vietnam, Singapore, and other jurisdictions currently running near-total prohibition don't have to choose between the American cascade and the European wellness-market opening. There's now a documented third option: pharmaceutical access bolted tightly to a narcotics-control framework, with enforcement getting sharper, not softer, as the medical lane opens.
The signals worth actually watching from here aren't going to look like news. They're going to look like committee votes and licensing filings. Does Korea's domestic production bill, with its Medical Narcotics Raw Material Management Center, clear the National Assembly, or does it stall the way plenty of narcotics-adjacent legislation has in Korean politics before? Do Japan's Type II licensees -- the small number of vetted cultivators -- actually get product through New Drug Application review and into pharmacies, or does the license class exist on paper for years before anything ships? Those are boring bureaucratic milestones by design. They're also the only ones that will actually tell you whether these markets move.
The single biggest mistake available to anyone watching this region is projecting a Western opening onto it -- assuming that because medical access expanded, recreational or wellness liberalization is next on some universal timeline. Japan's own law argues against that reading explicitly, by modeling itself on opioid regulation rather than on any cannabis-specific liberalization elsewhere. The more useful comparison, and the one both governments are effectively handing observers themselves, is Japan's historical handling of controlled pharmaceuticals -- slow, incremental, tightly held, decades between steps -- not America's state-by-state cascade or Europe's broader retail experiments. Read it on its own terms, and the next decade in Northeast Asia looks less like a slow march toward legalization and more like a permanent, carefully bordered medical lane running parallel to enforcement that keeps getting harder.
